Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%

Galderma

Status and phase

Completed

Phase 4

Conditions

Plaque Psoriasis

Treatments

Drug: Clobex Spray

Study type

Interventional

Funder types

Industry

Identifiers

NCT01893567

GLI.04.SPR.US10243

Details and patient eligibility

About

The aim of this study is to investigate the utility of a technological based rating scale for assessing improvement in plaque psoriasis with Clobex spray treatment.

Enrollment

28 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects 18 years of age or older.
Subjects with a board certified dermatologist clinical diagnosis of active moderate to severe psoriasis lesions affecting up to 20% of the body surface area at the baseline visit, and in the opinion of the investigator, is otherwise a good candidate for treatment with clobetasol propionate 0.05% spray.
Subjects with a target lesion of at least 1 cm x 1 cm
Subjects who agree to be photographed at each visit

Exclusion criteria

Subjects with any condition or presentation that may, in the opinion of the investigator, may put the subject at risk, may confound study results, or may interfere with participation in the study.
Subjects with any known allergies to any of the ingredients listed on the test article label or surgical ink.
Subjects who are pregnant or breast-feeding, or who plan to become pregnant or breast feed during the course of the trial.
Subjects that are relatives of the investigator, or are themselves or a relative of any study staff or any Galderma employee.
Subjects who have participated in an investigational study within 30 days of enrollment; participated in biologic investigational studies within 90 days of enrollment, or subjects planning to participate in any other interventional clinical research study while enrolled in this trial.